Mama

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Contactos do Centro de Ensaio	Investigador Principal	Estado*	Nº EudraCT
Hospital Beatriz Ângelo Avenida Carlos Teixeira, 3 2674-514 Loures - Portugal	Dra. Mafalda Casa-Nova	Recrutamento	2013-003839-30
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Dra. Fátima Cardoso	Recrutamento	2013-003839-30
Hospital CUF Descobertas Rua Mário Botas (Parque das Nações) 1998-018 Lisboa - Portugal	Dra. Sofia Braga	Recrutamento	2013-003839-30
Hospital da Luz Avenida Lusíada, 100 1500-650 Lisboa - Portugal	Dra. Mónica Nave	Recrutamento	2013-003839-30
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dr. António Moreira	Recrutamento	2013-003839-30

SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital de Braga Lugar de Sete Fontes, S. Vitor 4710-243 Braga - Portugal	Dra. Catarina Portela	Recrutamento	2015-000340-42
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Dra. Fátima Cardoso	Recrutamento	2015-000340-42

Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH / PHM: an open-label multicenter randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dr. António Moreira	Recrutamento	2011-006342-32
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Dra. Fátima Cardoso	Recrutamento	2011-006342-32

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital de Santa Maria Av. Prof. Egas Moniz 1649-035 Lisboa - Portugal	Dra. Rita Sousa	Recrutamento	2016-004740-11

A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, EPE Rua Dr. António Bernardino de Almeida 4200-072 Porto	Dra. Cláudia Vieira	Recrutamento	2016-002453-38

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital CUF Descobertas Rua Mário Botas (Parque das Nações) 1998-018 Lisboa - Portugal	Dra. Sofia Braga	Recrutamento	2015-002801-12

Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-002821-39
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Ana Ferreira	Recrutamento	2017-002821-39

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-002361-22
Centro Hospitalar Universitário Lisboa Norte Avenida Professor Egas Moniz 1649-035 Lisboa - Portugal	Dra. Maria Rita Dionísio	Recrutamento	2017-002361-22

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar do Porto Largo do Prof. Abel Salazar 4099-001, Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2015-002801-12

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar do Porto Largo do Prof. Abel Salazar 4099-001, Porto - Portugal	Informação não disponível	Recrutamento	2017-004869-27
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Marta Ferreira	Recrutamento	2017-004869-27

A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Universitário Lisboa Norte Avenida Professor Egas Moniz 1649-035 Lisboa - Portugal	Dra. Leonor Ribeiro	Recrutamento	2018-002153-30
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Susana Sousa	Recrutamento	2018-002153-30

Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Universitário do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-003131-11
Centro Hospitalar de Vila Nova de Gaia/Espinho Rua Conceição Fernandes, s/n 4434-502 Vila Nova de Gaia - Portugal	Dr. António Moreira Pinto	Recrutamento	2017-003131-11
Hospital Beatriz Ângelo Avenida Carlos Teixeira, nº 3 2674-514 Loures - Portugal	Prof. Dr. José Luís Passos Coelho	Recrutamento	2017-003131-11
Unidade Local de Saúde de Matosinhos Hospital Pedro Hispano Rua de Dr. Eduardo Torres Senhora da Hora - Portugal	Dra. Matilde Salgado	Recrutamento	2017-003131-11

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira - Guimarães Rua dos Cutileiros, 114 - Creixomil 4835-044 Guimarães	Dra. Alexandra Teixeira	Recrutamento	2016-002676-27